Bison conservation ranching on Blue Valley Ranch

Presented at the 8th international congress for wildlife and livelihoods on private and communal lands: livestock, tourism, and spirit, that was held on September 7-12, 2014 in Estes Park, Colorado.Video presenter: Perry Handyside.For 20 years, Blue Valley Ranch has been practicing conservation ranching in the Rocky Mountains of north-central Colorado with a focus on wildlife and agricultural production. An integrated resource management approach to land stewardship guides its planning process, and an adaptive management philosophy helps to make management decisions based on science and monitoring feedback. The ranch's vision of conserving wildlife habitat, building ecosystem resiliency, and producing quality livestock and forage crops is exemplified in the inclusion of the American bison (Bison bison) in its operation. As a native grazer, bison are a natural choice for raising a healthy food product on native ranges while practicing good land stewardship. Though hunted to near extinction in the late 19th century, bison have made a comeback in recent decades, due in large part to conservation-minded ranchers and private landowners. A clear understanding of their behavior and grazing ecology takes advantage of the bison's evolutionary history with the grasslands and shrublands of the western United States, and makes them a perfect fit for private lands conservation interested in supporting agriculture and healthy ecosystems

RWE in Europe Paper II: The use of Real World Evidence in the disease context

Real World Evidence (RWE), the use of data not collected via traditional randomised controlled trials (RCT) for decision-making, is becoming more interesting to market-access and reimbursement decision-makers, despite potential methodological issues around its use. This paper, the second in a series looking at the use of Real World Evidence (RWE) in Europe, analyses the opinions of a number of key experts in pricing and reimbursement from a selection of countries across Europe. Discussion centred on the use of RWE in licensing, commissioning, clinical decision-making and patient and outcome related decision-making in the context of three different treatment areas – chronic disease, oncology and rare diseases. Results of discussion sessions with ‘RWE experts’ indicated that the associated benefits of RWE are becoming more relevant but there is a need for a well-organised, high quality system for data generation, interpretation and use. It is likely that different treatment areas will have differing RWE requirements and differing levels of utility. In the rare disease arena, RWE may have a role in licensing based decisions, but this is unlikely for chronic disease or oncology. In order to enhance the role of RWE, and to ensure it meets its full potential in all treatment areas, a multi-stakeholder approach at the EU level is required, with collaboration between national and supranational organisations and all stakeholders including patient organisations, manufacturers and reimbursement agencies

RWE in Europe Paper III: A Roadmap for RWE

Real world evidence (RWE) has been touted as a remedy for current market access issues, facilitating quicker approvals and increased odds of reimbursement at a good price. It is therefore an attractive avenue for pursuit for manufacturers today. This paper, the third in a series looking at the use of RWE in Europe, outlines the discussions held between key opinion leaders in pricing and reimbursement across a number of European countries at a roundtable-style meeting. The aim of the meeting was to develop a 3-year roadmap, and resulting action plan, of initiatives for the enhanced use of RWE in decision-making in the pharmaceutical industry. Following a series of brainstorming sessions across the areas of commissioning and access, clinical evidence and patients and outcomes, contributors were asked to prioritise the importance of a refined set of initiatives identified in these brainstorming sessions to develop the three-year road map. Finally, four key points from the roadmap were identified for initial action: actively engage in early dialogue with payers on RWE needs; consensus exercise on RWD/E in clinical decisions, develop a definition of patient reported/relevant outcomes and develop a model approach for the collection of patient reported/relevant outcomes data. These action points are seen as the most imperative steps for enhancing the role of RWE. If its use is to become more common addressing these steps, as quickly and efficiently as possible, will be vital for all stakeholders in the pharmaceutical arena

RWE in Europe Paper IV: Engaging pharma in the RWE Roadmap

This paper summarises discussions held at the fourth round-table style meeting with a group of expert stakeholders with experience in specialist disease areas and commissioning of care plus prior experience in the field of real world evidence (RWE). The aim of these meetings was to gain an understanding of the use of RWE across Europe and to develop a road map of initiatives for the pharmaceutical industry in order to enhance their use of RWE. This, the fourth and final paper in this series, outlines the future potential of the stakeholder group involved in the project to date

Sharp-tailed grouse reintroduction projects on Blue Valley Ranch

Moderator: Terry Riley.Presented at the 8th international congress for wildlife and livelihoods on private and communal lands: livestock, tourism, and spirit, that was held on September 7-12, 2014 in Estes Park, Colorado.Video presenter: Josh Richert.The Columbian Sharp-tailed Grouse (Tympanuchus phasianellus columbianus; CSTG) is the rarest of six sub-species of grouse that are endemic to sagebrush, shrubsteppe and mountain shrub communities of western North America. It currently occupies less than 10% of its historic range, including 3 counties in northwestern Colorado, due to habitat loss, energy development, changes in land management and urban expansion. CSTG populations had been documented in the Lower Blue River Basin of Middle Park in North-Central Colorado as recently as the mid-1950s, so a cooperative effort between Colorado Parks and Wildlife (CPW) and private landowner Blue Valley Ranch (BVR) sought to re-introduce the bird to this area. Trapping occurred from the Fall 2006 - Spring 2008 seasons in the Hayden and Craig areas of Northwestern Colorado. A total of 91 females and 58 males were released on Blue Valley Ranch from 2006 - 2008. Approximately 15 males and 27 females were deployed with VHF radio transmitters for monitoring. Habitat and nesting data were also collected for comparison with the trapping area. Since the release, two permanent leks have been established with high counts of 21 and 26 males in 2014, with two additional lek sites needing confirmation in 2015. The project has been successful in establishing a new population of CSTG on a private, 25,000 acre conservation ranch within their historical range, and CPW plans to augment the population with additional CSTG releases over the next 2-3 years in the Williams Fork Drainage, about 8 miles east of BVR

Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach

Background: Teprotumumab is the first treatment for thyroid eye disease (TED), a debilitating autoinflammatory condition, approved by the Food and Drug Administration in the United States, which reduces proptosis and improves quality of life. In the absence of guidelines, clinical recommendations were developed for using teprotumumab in patients with TED in the United States. Methods: A 3-round modified-Delphi panel was conducted between October 2020 and February 2021 with experts in the management of patients with TED. Key areas regarding the use of teprotumumab were investigated, including eligible patient populations, concomitant treatments, and assessment of response and adverse events. This used 2 survey rounds via an online questionnaire, where statements were scored using 9-point Likert scales. Statements with conflict were included in the third round, involving a consensus meeting via videoconference. Results: Consensus was obtained for all statements (n = 75); of which, 56% were revised to enable agreement of the group. The consensus meeting provided agreement regarding which populations should receive teprotumumab therapy, including all adult patients with TED with a clinical activity score of ≥4. Treatment with teprotumumab can also be considered for TED patients displaying the following characteristics: a CAS of <3, lid retraction of ≥2, and mild or early optic neuropathy with close clinical observation. Further recommendations included suitability of treatment for those beyond 16 months following the initial diagnosis of TED, low CAS concomitant treatment with steroids in some cases, retreatment for those who have relapses, and finally a recommendation to continue therapy for all 8 infusions despite the lack of response by the fourth infusion. Conclusions: This work constitutes the first consensus on guidelines for the use of teprotumumab. The modified Delphi approach involved physicians with significant experience with the clinical use of teprotumumab, and recommendations were based on current evidence

Magnetism and superconductivity in Sr

We report magnetization, surface resistance ($R_{\rm s}(T,H)$), and electron spin resonance (ESR) for non-superconducting Ba2GdRu2CuuO6, and find that all three magnetic ions (Gd, Ru, and Cu) are ordered at low temperatures. Both ESR (Gd sublattice) and weak ferromagnetic resonance (dopant Cu) are observed, while no magnetic resonance due to either paramagnetic or ordered Ru is detected. In addition, for superconducting ($T_{\rm c}\sim45$ K) Sr2YRu1-uCuuO6, resistivity, muon spin rotation (µ+SR), and 99Ru Mössbauer absorption are reported. None of the O6 materials (e.g., Sr2YRu1-uCuuO6) have cuprate planes, although Cu is employed as a dopant. In Sr2YRu1-uCuuO6, the Ru moments order at a temperature (∼23 K) below that for the resistive onset of superconductivity, while the Cu orders at a higher temperature, ∼86 K. Therefore at low temperatures, this material exhibits magnetic order, coexisting with diamagnetism. The only non-magnetic layers in the superconducting O6 structure, the SrO layers, carry holes and exhibit diamagnetic screening characteristic of type-II superconductivity